Preclinical efficacy of an antibody-drug conjugate targeting mesothelin correlates with quantitative89 Zr-ImmunoPET

Anton G.T. van Terwisscha Scheltinga, Annie Ogasawara, Glenn Pacheco, Alexander N. Vanderbilt, Jeff N. Tinianow, Nidhi Gupta, Dongwei Li, Ron Firestein, Jan Marik, Suzie J. Scales, Simon-Peter Williams

Research output: Contribution to journalArticleResearchpeer-review

27 Citations (Scopus)


Antibody-drug conjugates (ADC) use monoclonal antibodies (mAb) as vehicles to deliver potent cytotoxic drugs selectively to tumor cells expressing the target. Molecular imaging with zirconium-89 (98Zr)-labeled mAbs recapitulates similar targeting biology and might help predict the efficacy of these ADCs. An anti-mesothelin antibody (AMA, MMOT0530A) was used to make comparisons between its efficacy as an ADC and its tumor uptake as measured by 89Zr immunoPET imaging. Mesothelin-targeted tumor growth inhibition by monomethyl auristatin E (MMAE), ADC AMA-MMAE (DMOT4039A), was measured in mice bearing xenografts of ovarian cancer OVCAR-32.1, pancreatic cancers Capan-2, HPAC, AsPC-1, and HPAF-II, or mesothelioma MSTO-211H. Ex vivo analysis of mesothelin expression was performed using immunohistochemistry. AMA-MMAE showed the greatest growth inhibition in OVCAR-32.1, Capan-2, and HPAC tumors, which showed target-specific tumor uptake of 89Zr-AMA. The less responsive xenografts (AsPC-1, HPAF-II, and MSTO-211H) did not show 89Zr-AMA uptake despite confirmed mesothelin expression. ImmunoPET can demonstrate the necessary delivery, binding, and internalization of an ADC antibody in vivo and this correlates with the efficacy of mesothelin-targeted ADC in tumors vulnerable to the cytotoxic drug delivered.

Original languageEnglish
Pages (from-to)134-142
Number of pages9
JournalMolecular Cancer Therapeutics
Issue number1
Publication statusPublished - Jan 2017
Externally publishedYes

Cite this